• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
CRBP

CRBP

Corbus Pharmaceuticals Holdings, Inc.

NASDAQHealthcareBiotechnologyUS

USD7.38

-0.16 (-2.12%)

Rating:B-

Company Profile

CEO

Yuval Cohen

IPO Date

2014-10-27

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$7.49

Prev. Close

$7.54

Day Low

$7.35

Day High

$7.71

52W Low

$6.72

52W High

$20.56

Market Cap

$0.09B

Volume

0.51M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

31.3%

Avg Negative

11.5%

Avg Neutral

57.1%

News Feed

Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research·8/12/2021·↑ positive

Recap: Corbus Pharmaceuticals Q2 Earnings

Benzinga·8/12/2021·↓ negative

Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates

GlobeNewsWire·8/12/2021·↑ positive

Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Zacks Investment Research·7/29/2021·↑ positive

Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

GlobeNewsWire·6/24/2021·↑ positive

CRBP Stock Price: Over 9% Increase Pre-Market Explanation

Pulse2·6/1/2021·↑ positive

Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases

GlobeNewsWire·6/1/2021·↑ positive

Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress

GlobeNewsWire·5/25/2021·↑ positive

CORBUS PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING

GlobeNewsWire·5/19/2021·↑ positive

Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates

GlobeNewsWire·5/13/2021·↑ positive